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ABSTRACT 
 
Objective  
The aim was to investigate the contribution of liver steatosis and significant fibrosis alone 
and in association (NAFLD with fibrosis) to frailty as a measure of biological age in people 
living with HIV (PLWH). 
Design 
This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic 
Clinic in 2018-2019. 
Methods 
Patients with hazardous alcohol intake and viral hepatitis co-infection were excluded. Liver 
steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was 
diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver 
steatosis (CAP≥248), while significant liver fibrosis or cirrhosis (stage F2) as LSM>7.1 
kPa. Frailty was assessed using a 36-Item frailty index (FI). Logistic regression was used to 
explore predictors of frailty using steatosis and fibrosis as covariates. 
Results 
We analyzed 707 PLWH (mean age 53.5 years, 76.2% males, median CD4 700 μL, 98.7% 
with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9% and 3.9% 
of patients were classified as frail and most-frail, respectively. Univariate analysis 
demonstrated that neurocognitive impairment (OR=5.1, 1.6-15), vitamin D insufficiency 
(OR=1.94, 1.2-3.2), obesity (OR=8.1, 4.4-14.6), diabetes (OR=3.2, 1.9-5.6) and osteoporosis 
(OR=0.37, 0.16-0.76) were significantly associated with NAFLD with fibrosis. Predictors of 
FI included : steatosis (OR=2.1, 1.3-3.5), fibrosis (OR=2, 1-3.7), NAFLD with fibrosis 
(OR=9.2, 5.2-16.8), diabetes (OR=1.7, 1-2.7) and multimorbidity (OR=2.5, 1.5-4).  
Conclusion 
Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis 
exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of 
metabolic age in PLWH. 
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Background 
Non-alcoholic fatty liver disease (NAFLD) has become an emerging condition in general 
aging population and the most common cause of chronic liver disease [1]. The predictions 
show that NAFLD prevalence will increase by 21%, from 83.1 million in 2015 to 101 million 
in 2030 in the United States [2]. NAFLD is defined as fat accumulation in >5% hepatocytes 
not attributable to consumption of alcohol and may be associated to fibrosis. Both steatosis 
and fibrosis could be diagnosed by non-invasive diagnostic tools, such as transient 
elastography (TE) with controlled attenuation parameter (CAP). On the other side, the 
diagnosis of non-alcoholic steatohepatitis (NASH) is based on liver biopsy that combines 
liver steatosis with hepatocyte ballooning and lobular inflammation, that potentially leads to 
progressive liver fibrosis and hepatic failure [1].  
 
Recent studies confirm the increasing burden of NAFLD in people living with HIV (PLWH), 
as viral hepatitis prevalence and associated mortality decline [3]. Moreover, liver disease is a 
leading cause of non-AIDS related deaths in PLWH [4]. 
 
Nevertheless, NAFLD should not be considered as a liver condition only, but rather as a 
multisystemic state involving other organs [5]. Indeed, NAFLD has been linked to increased 
risk of type 2 diabetes mellitus, cardiovascular disease, and chronic kidney disease in the 
general population. In this scenario, NAFLD is not only seen as a risk factor, but can play an 
important role in the complex pathogenesis of non-infectious co-morbidities (NICMs) [5]. 
This relationship remains unexplored in PLWH, despite metabolic syndrome and its 
components are frequent and consistently reported as risk factors for NAFLD in this 
population [6]. 
Accumulation of NICMs described by multimorbidity, is a typical feature in people reaching 
geriatric age, nevertheless this construct fails to describe the clinical complexity of aging. For 
this reason, geriatric medicine has conceptualized the construct of frailty to identify 
individuals more vulnerable to adverse health outcomes and to provide suitable clinical 
interventions.   
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So far, it has been shown that frailty represents a more accurate measure of an individual’s 
biological age that may replace the traditional metric of chronological age, which does not 
necessarily correspond [7]. Frailty is defined as a condition characterized by the reduction of 
homeostatic reserves exposing the individual to a greater risk of negative outcomes such as 
multimorbidity, falls, disability, nursing home placement and death [8].  
In the clinical setting, how to measure frailty is still a matter of debate. At the organ level, 
sarcopenia assessment has been proposed as an equivalent of frailty, while for a more 
profound and holistic approach, frailty phenotype and frailty index had been used [9]. In fact, 
while sarcopenia is an important component of frailty, it may be seen as a one-dimensional 
approach, while the aging in an individual is a complex process where multiple factors play a 
role. The association of NAFLD and sarcopenia has been investigated both in HIV and the 
general population [10–12]. Our group has recently reported that sarcopenia assessed by grip 
strength increased the risk of NAFLD [13], while the data regarding association between 
NAFLD and frailty remains scarce (Supplementary figure 1).  
We hypothesized that NAFLD could be a significant determinant of frailty, in the context of a 
multisystemic nature of both these conditions. Therefore, the objective of the study was to 
investigate the correlation between liver steatosis and significant fibrosis alone and in 
association (NAFLD with fibrosis) and frailty, as a measure of biological age, in PLWH. 
Material and methods 
Study design 
This was a cross-sectional study that included consecutive PLWH attending Modena HIV 
Metabolic Clinic (MHMC) from June 2018 to May 2019. MHMC is a tertiary level referral 
center established in 2004 where PLWH are screened for NICMs and immuno-metabolic 
disorders including NAFLD, geriatric syndromes and frailty to better describe their aging 
trajectory.  
 
Inclusion and exclusion criteria   
We included ART-experienced PLWH who were evaluated for liver steatosis and fibrosis by 
transient elastography at MHMC. Patients with hepatitis B (HBV), hepatitis C (HCV) co-
infection and hazardous alcohol intake were excluded from the study. HBV and HCV co-
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infection diagnosis were based on serology, while the alcohol intake was evaluated through 
an AUDIT questionnaire that collects self-reported information, using as cut-offs 30g/day for 
men and 20g/day for women [14].  
 
Assessment of steatosis and fibrosis 
Liver stiffness measurement (LSM) and associated CAP were evaluated using TE with M 
probe. Liver steatosis was diagnosed by CAP as follows: S0 (no steatosis; CAP<248 dB/m), 
S1 (mild steatosis; 248≥ CAP <268 dB/m), S2 (moderate steatosis; 269≥ CAP<280 dB/m), 
S3 (severe steatosis; CAP≥ 280 dB/m) [15]. All measurements >248 dB/m were considered 
as NAFLD. Liver fibrosis was diagnosed by LSM as follows: stage F0-F1 (mild fibrosis, 
LSM<7.1 kPa), F2-F3 (significant fibrosis, 7.1≥LSM<13 kPa), F4 (cirrhosis, LSM≥13 kPa) 
[16].  
NAFLD with fibrosis was defined as the contemporary presence of liver steatosis (CAP≥248) 
and significant liver fibrosis or cirrhosis (stage ≥F2). In the unavailability of liver biopsy, we 
considered NAFLD with fibrosis as a proxy of NASH . 
 
Covariates 
Demographic, anthropometric, HIV-related and immune-metabolic variables were collected 
on the same day of the visit at MHMC. Co-morbidities were defined using the European 
AIDS Clinical Society (EACS) guidelines [17]. Hypertension was defined as two consecutive 
measurements of blood pressure >140/90 mmHg. T2DM was defined as fasting serum 
glucose levels >126 mg/dL or HbA1C >6.5%. Diagnoses of hypertension and T2DM were 
also identified based on the current use of antihypertensive or antidiabetic drugs. Obesity was 
diagnosed as body mass index (BMI) > 30 kg/m
2
. Dyslipidemia was defined as elevated total 
or low density lipoprotein (LDL) cholesterol or low high density lipoprotein (HDL) 
cholesterol above laboratory limits. Chronic kidney disease (CKD) as an estimated 
glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2 calculated using the CKD-Epi 
equation. Laboratory values for the diagnosis of CKD and dyslipidemia were confirmed in 
two consecutive measurements. Metabolic syndrome was defined using MetS ATPIII 
classification [18], including three or more of the following five criteria: waist circumference 
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over 102 cm (men) or 88 cm (women), blood pressure over 130/85 mmHg, fasting 
triglyceride level over 150 mg/dl, fasting HDL cholesterol level less than 40 mg/dl (men) or 
50 mg/dl (women), and fasting blood glucose over 100 mg/dl [18]. Cardiovascular disease 
included myocardial infarction, coronary artery disease, peripheral vascular disease, stroke, 
and angina pectoris, as well as coronary artery bypass grafting and angioplasty, based on 
diagnoses recorded in patient files. Chronic obstructive pulmonary disease was defined as 
post-bronchodilator FEV1/FVC <0.70 with spirometry. Vitamin D insufficiency was defined 
as < 20 ng/mL (< 50 nmol/L). Osteoporosis in postmenopausal women and men aged ≥50 
years was defined as a bone mass index (BMD) T-score ≤-2.5 and in premenopausal women 
and men aged <50 years as a BMD Z-score ≤-2 and fragility fracture. The presence of a 
cancer was considered if a diagnosis was reported in the patient’s medical history. Depression 
was evaluated using the CES-D questionnaire. Neurocognitive impairment was evaluated 
using CogState battery that comprises six tasks, one for each cognitive domain [19]. Multi-
morbidity was defined as ≥2 comorbidities in the same individual. 
 
Frailty assessment 
Frailty was determined using 36-Item frailty index (FI) generated by a standardized 
comprehensive geriatric assessment, previously validated at MHMC and constructed from 
health variables collected at the same study visit (Supplementary table 1). Each variable 
included in the FI was coded with a value of 1 when a deficit was present, and 0 when it was 
absent. Missing values were removed from both the numerator and the denominator of the FI 
[20]. The FI for each patient visit was calculated as the ratio between the number of deficits 
present and the total number of deficits assessed. Missing values were removed from both the 
numerator and denominator of the FI (FI = 
        
(                 )
 ). Each FI was computed when 
a minimum of 80% of valid data for the health variables was available. We categorized 
PLWH according to FI score as fit (<0.25), frail (0.25-0.4), most frail (>0.4) [21]. Of note, 
NAFLD, selected as a covariate of interest for this study, was excluded from the computation 
of the FI. 
Statistical analysis  
Results were expressed as mean and standard deviation (± SD), or median and interquartile 
range (IQR) for continuous variables based on the normality of distribution, and as 
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frequencies and percentages for categorical variables. Student’s t-test and ANOVA were 
applied to identify statistical difference for the continuous variables with normal distribution, 
while the Mann-Whitney and Walls-Kruskal test was used for those without normal 
distribution. The χ2 test was performed to assess the frequency of the categorical variables. 
Logistic regression models were built to explore the contribution of liver steatosis and 
significant fibrosis alone and in association (NAFLD with fibrosis) to frailty along with age, 
gender, diabetes mellitus and multi-morbidity. Multivariate regression models included 
covariates with a p-value<0.05 in univariable analysis or covariates that were determined a 
priori to be clinically important, based on previous literature. 
 
Subgroups of PLWH with liver steatosis, significant fibrosis and NAFLD with fibrosis were 
mutually exclusive. The missing data was removed from denominator and was not considered 
in the calculations. The numbers between square brackets [N°] refer to number of people in 
which the given variable was available. The significance of the tests was set to 0.05. The 
statistical program R, v. 3.6.0 in GNU Linux environment was used to analyze the data. 
 
This study was approved by the University of Modena and Reggio Emilia ethics committee 
according to the Helsinki declaration. 
Results 
We analyzed 707 PLWH. Mean age was 53.5 (8.2) years, 76.2% were males, mean BMI 
was 24.6 (4.2), 18.3% had T2DM, median CD4 was 700 μL (IQR=540-889), HIV RNA 
viral load was undetectable in 98.7% of cases. Prevalence of NAFLD was 39.7%, while 
NAFLD with fibrosis was present in 10.2%, frail and most-frail in 18.9% and 3.9%, 
respectively. Study population characteristics according to frailty index categories is provided 
in Supplementary table 2. Detailed description of liver steatosis and fibrosis is provided in 
Supplementary table 3. 
 
Supplementary figure 2 depicts trends of prevalence of steatosis, fibrosis and NAFLD with 
fibrosis across different chronological age categories (<45, 46-50, 51-55, 56-60, 61-65, >65 
years). The highest peaks for all three conditions are observed in PLWH at the age of 51-55 
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(43.4%, 21.4% and 15.1% respectively) and at the age 65+, which is defined as geriatric age 
(46.2%, 25.6% and 15.4% respectively).  
 
With regards to a biological age, assessed by FI, prevalence of frailty increased with higher 
levels of liver steatosis and fibrosis, and NAFLD with fibrosis (Figure 1). Frailty was present 
in 41.2% and 52.3% in PLWH with mild/moderate and severe liver steatosis respectively 
(Figure 1A, p<0.001). A similar pattern is observed for liver fibrosis, i.e. FI scores >0.25 
were found in 54.8% and 70% PLWH with significant fibrosis and cirrhosis, respectively 
(Figure 1B, p<0.001). In PLWH with NAFLD with fibrosis, frailty was identified in 69% 
(Figure 1C, p<0.001). 
 
NAFLD with fibrosis group showed a higher prevalence of obesity (36% vs. 6%) (p<0.001) 
(Table 1). With regards to HIV variables, PLWH with NAFLD with fibrosis presented a 
longer mean HIV duration and lower CD4 nadir. The use of NNRTI was observed in 24% of 
PLWH with more than two times higher use in people without NAFLD with fibrosis. This 
observation was accompanied by higher HDL cholesterol levels, while LDL and total 
cholesterol levels were lower (Table 1). 
 
Univariate analysis demonstrated that neurocognitive impairment (OR=5.08, 1.61-14.96), 
vitamin D insufficiency (OR=1.94, 1.18-3.24), obesity (OR=8.06, 4.44-14.55), diabetes 
mellitus (OR=3.24, 1.91-5.59) and osteoporosis (OR=0.37, 0.16-0.76) were associated with 
NAFLD with fibrosis (Table 2). 
To better explore this association, a multivariate logistic model was built. Independent 
positive predictors for FI were steatosis (OR=2.12, 1.3-3.45) and fibrosis (OR=1.95, 1.03-
3.66) alone and in association – NAFLD with fibrosis (OR=9.19, 5.17-16.79), diabetes 
mellitus (OR=1.65, 1-2.74) and multimorbidity (OR=2.46, 1.53-4.01) (Figure 2).   
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Discussion  
The relationship between liver steatosis and significant fibrosis alone and in association 
(NAFLD with fibrosis) and frailty is not a widely investigated topic in PLWH and general 
population. 
 
This study explored in detail liver steatosis and fibrosis in relation to chronological age and 
frailty as a proxy of biological age. With regards to chronological age, steatosis and NAFLD 
with fibrosis follow the same trend of prevalence across age groups in our study. The curves 
have an initial increase until the age of 50, followed by a plateau that occurs between 50-65. 
The prevalence of NAFLD across age remains controversial. Most studies showed that 
NAFLD prevalence increases with advancing age  [22]. However, the cross-sectional nature 
of the study and a small subset of patients older than 65 years do not permit us to make strong 
conclusions about prevalence of liver steatosis and NAFLD with fibrosis in geriatric PLWH.  
 
It remains unclear if NAFLD with fibrosis is regulated by age or is a regulator of biological 
age itself. According to the second scenario, NAFLD with fibrosis would reflect better 
biological age (frailty) of the individual, consistent with our initial hypothesis and the main 
finding. NAFLD with fibrosis and frailty showed almost a linear association. In our 
multivariate analysis, NAFLD with fibrosis was associated with frailty, 3-fold more than 
multimorbidity, suggesting that NAFLD with fibrosis as a multisystemic construct [5] 
exceeds the construct of multimorbidity, defined as a simple sum of single NICMs. Given 
this strong association with frailty as a measure of biological age, we may suggest NAFLD 
with fibrosis as an indicator to assess the metabolic age of an individual. From the present 
study emerges lack of association between chronological age and frailty index, both in 
univariate and multivariate analysis. This is not consistent with previous studies from our 
group and to what was shown in general population [21]. Such finding could be justified by 
different of cut-offs to identify frail individuals or choice not to use FI as a continuous 
variable, as in the previously quoted study [21].  
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Our multivariate analysis showed that male gender is protective against frailty, which is in 
line with observations in general population [23]. In HIV setting were identified different 
variables associated with frailty in males (VACS index, C-reactive protein and falls) and 
females (CRP, AIDS, and menopause) [24]. These observations imply that choice of 
variables that entered in the frailty index used in our study might have played a role in the 
gender difference. However, further studies are needed to investigate patterns of frailty with 
the regards to gender. 
 
As expected, obesity, BMI, waist circumference, higher aminotransferase, GT and 
triglycerides and lower HDL levels were strongly associated with NAFLD with fibrosis 
suggesting that PLWH share common metabolic patterns occurring in the general population 
[25]. Similar findings were obtained in a large cohort study that comprised PLWH with and 
without metabolic syndrome in which obesity and insulin resistance were key factors 
associated with liver fibrosis independently of the HIV duration and exposure to ART [26]. 
However, the pathogenesis of NAFLD in PLWH has some additional features [27], expressed 
by viro-immunological parameters, depicted by low nadir and longer HIV duration or other 
factors that may contribute to immune activation in PLWH. This suggests that also an 
“immunological scar” that might be depicted by higher levels of sCD163 is associated with 
metabolic harm and hepatic inflammation, captured by NAFLD with fibrosis [26]. 
 
We arbitrary chose a definition of NAFLD with fibrosis based on the European Association 
for the Study of the Liver (EASL) definitions of liver steatosis and fibrosis singularly 
evaluated with TE [16]. This combined definition was used in order to offer a proxy 
measurement of NASH. Liver fibrosis, as the most important histological determinant of 
NASH, is associated with long-term negative outcomes in the general population and PLWH 
[28,29].    
 
We found that not only NAFLD with fibrosis, but also liver steatosis was associated with 
frailty, implying that health care interventions that are proven to be effective, such as weight 
loss and other lifestyle changes [30,31], should be reinforced and promoted in order to 
decrease the burden of frailty, as well as the burden of NAFLD with fibrosis in PLWH.  
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In patients in which lifestyle changes are not sufficient to treat NAFLD/NASH, some other 
therapeutic options are considered, such as pharmacologic treatment or liver transplantation 
[32,33]. In the last few years, an increased number of clinical trials for treatment of 
NAFLD/NASH are noted [34,35], recognizing this condition as one of the major challenges 
in contemporary and future health care. We observed that 69% of PLWH with NAFLD with 
fibrosis were frail in our study. The only validated test to prove NASH is liver biopsy [1,16]. 
NASH diagnosis is rarely made because of the unavailability and invasiveness of liver 
biopsy, implying that the selection of the affected patients for pharmacologic treatment will 
also be an issue. Frailty assessment could serve as an additional criterion in decision making, 
as it is more feasible in the routine clinical practice.  
 
This study has a number of limitations. Some of these are intrinsic to the cross-sectional 
nature of the study, which cannot reveal a causative association between NAFLD with 
fibrosis and frailty. The absence of a control group does not allow us to show whether 
demographic, anthropometric, HIV variables and comorbidities associated both with NAFLD 
with fibrosis and frailty represent a different pattern of PLWH when compared to the general 
population. 
 
In conclusion, liver steatosis and fibrosis alone and in association were associated with 
frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting 
the former as an indicator of metabolic age in PLWH. 
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Figure 1 shows the association between frailty index divided into three groups (fit (<0.25), 
frail (0.25-0.4), most frail (>0.4)) and liver steatosis (1A), liver fibrosis (1B) and NAFLD 
with fibrosis (1C). Abbreviations: F0-F1 – mild fibrosis; F2-F3 – significant fibrosis; F4 – 
cirrhosis; S0 – without steatosis; S1-S2 – mild-moderate steatosis; S3 – severe steatosis. 
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Figure 2 depicts a multivariate logistic model that identified independent predictors for FI 
were liver steatosis and fibrosis alone and in association (NAFLD with fibrosis), diabetes and 
multi-morbidity. Abbreviations: MM – multimorbidity; T2DM – type 2 diabetes mellitus. 
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 Variable NAFLD without 
fibrosis 
NAFLD with 
fibrosis 
p 
N 635 (89.8%) 72 (10.2%)  
Sex, male (%) 479 (75.4%) 60 (83.3%) 0.20 
Age, years, mean (SD), [N°] 53.2 (8.1) [635] 55.8 (8.2) [72] 0.02 
BMI, kg/m
2
, mean (SD), [N°] 24.2 (4) [633] 28.7 (4.2) [72] <0.00
1 
Waist circumference, cm, mean (SD), 
[N°] 
90.8 (34.4) [595] 104.9 (11.2) [67] <0.00
1 
Obesity (%) 38 (6%) 26 (36.1%) <0.00
1 
Mild/moderate physical activity (%) 292 (46%) 18 (25%) 0.001 
HIV duration, months, median (IQR), 
[N°] 
275 (165.5-338) 
[615] 
322 (229-372) 
[71] 
0.007 
Nadir CD4, median, c/µL, median 
(IQR) [N°] 
224 (100-328.8) 
[606] 
180 (67-287) [68] 0.03 
Current CD4, median, c/µL, median 
(IQR) [N°] 
700 (542.3-884.8) 
[622] 
689 (436-891) 
[69] 
0.39 
Current CD8, median, c/µL, median 
(IQR) [N°] 
778.5 (581.8-1038) 
[620] 
823 (550-1054) 
[69] 
0.92 
CD4/CD8 ratio, mean (SD), [N°] 1 (0.5) [620] 0.98 (0.5) [69] 0.65 
Undetectable viral load (%) 627 (98.7%) 71 (98.6%) 0.99 
Type 2 diabetes (%) 99 (15.6%) 30 (41.7%) <0.00
1 
Polypharmacy (%) 81 (12.8%) 17 (23.6%) 0.02 
Current exposure to NNRTI (%) 160 (28.1%) 9 (13.6%) 0.02 
FIB-4. mean (SD), [N°] 1.5 (0.9) [285] 1.6 (0.6) [37] 0.02 
AST, U/l, mean (SD), [N°] 24.1 (12.5) [605] 30.2 (14.9) [65] <0.00
1 
GT, U/L, mean (SD), [N°] 29 (28.9) [600] 48.1 (36) [65] <0.00
1 
Total cholesterol, mg/dl, mean (SD), 
[N°] 
180.9 (35.6) [603] 166.9 (41.9) [65] 0.003 
LDL cholesterol, mg/dl, mean (SD), 
[N°] 
117.8 (32.7) [600] 106.1 (38.7) [64] 0.004 
HDL cholesterol, mg/dl, mean (SD), 
[N°] 
51.6 (15) [600] 43.8 (10.6) [65] <0.00
1 
Triglycerides, mg/dl, mean (SD), [N°] 133.5 (90) [603] 169.8 (108.2) [64] 0.002 
Metabolic syndrome (%) 176 (27.7%) 49 (68.1%) <0.00
1 
Grip strength, kg, mean, (SD), [N°] 36 (9.6) [573] 37.3 (8.3) [68] 0.46 
4m walk speed test, seconds, mean, 
(SD) [N°] 
3.6 (0.6) [588] 3.8 (0.6) [66] 0.005 
30s chair-stand test, mean (SD) [N°] 8.1 (2.8) [603] 8.6 (2.8) [67] 0.12 
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Table 1 describes demographic, anthropometric HIV and clinical characteristics in PLWH with and 
without severe NAFLD. 
Abbreviations: AST - aspartate aminotransferase; BMI – body mass index; HDL – high 
density lipoprotein; HIV – human immunodeficiency virus; IQR – interquartile range; LDL – 
low density lipoprotein; [N°] – number of people in which the given variable was available; 
NAFLD – non-alcoholic fatty liver disease; NNRTI – non-nucleoside reverse transcriptase 
inhibitors; SD – standard deviation 
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Table 2. Univariate analysis demonstrates that neurocognitive impairment, vitamin D 
insufficiency, obesity, T2DM and osteoporosis are associated with NAFLD with fibrosis. 
 
Abbreviations: CKD – chronic kidney disease; COPD – chronic obstructive pulmonary 
disease; CVD – cardiovascular disease; IQR – interquartile range; NAFLD – non-alcoholic 
fatty liver disease; NC – neurocognitive, OR – odds ratio. 
 
 NAFLD with fibrosis 
OR IQR 
 
P 
Depression 1.78 0.93-3.31 0.07 
NC impairment 5.08 1.61-14.96 <0.01 
Vitamin D insufficiency  1.94 1.18-3.24 0.01 
Obesity 8.06 4.44-14.55 <0.01 
Hypertension 1.59 0.95-2.7 0.08 
Type 2 diabetes 3.28 1.91-5.59 <0.01 
CVD 0.85 0.25-2.29 0.78 
CKD 0.71 0.35-1.35 0.32 
COPD 1.32 0.38-3.57 0.62 
Osteoporosis 0.37 0.16-0.76 0.01 
Dyslipidemia  0.92 0.47-1.92 0.8 
Cancer 1.36 0.70-2.50 0.34 
Metabolic syndrome 2.41 1.47-3.95 <0.01 
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